503B bulks list
The list of substances outsourcing facilities may compound from bulk ingredients. The FDA’s April 30, 2026 proposed rule would strike semaglutide, tirzepatide, and liraglutide from it — effectively ending 503B production of these molecules if finalized; the comment period closed June 29, 2026 with the final rule pending.
Released · Last reviewed · how we verify
Seen against the November 20, 2026 re-read: compounded tirzepatide runs from $85.58 to $399 and semaglutide from $75.58 to $299 per billing cycle, all-in, among programs that print a comparable price, so terms like this one decide whether the advertised number matches the bill. Every definition in this glossary links back to the places in the database and the methodology where the concept does its work.
If the pending rule finalizes as proposed, the 503B half of this market’s supply ends — the largest single risk any prepaid commitment here carries. Related figures live on the pages this term links to, and every one of them regenerates from the same dataset this definition does.
See the term in action across the price database and the methodology.